Baidu
map

抗癌“登月计划”升级,拜登宣布将帮助更多肿瘤患者参与临床试验

2016-09-29 佚名 生物谷

美国副总统拜登提出的抗癌“登月计划”前段时间引起热议,标志着美国的肿瘤研究将获得更多的资金和政策上的支持。随着美国大选在即,副总统任期也所剩无几,近日拜登提出要帮助更多的患者加入到临床试验中,并增强他们的治疗效果。 具体而言,拜登宣布了一系列举措,旨在帮助患者更好地了解临床试验的相关信息,这些信息可能对于患者而言过于专业、难以理解,现在拜登提出的措施将有助于患者理解并加入临床试验。此外,还要

美国副总统拜登提出的抗癌“登月计划”前段时间引起热议,标志着美国的肿瘤研究将获得更多的资金和政策上的支持。随着美国大选在即,副总统任期也所剩无几,近日拜登提出要帮助更多的患者加入到临床试验中,并增强他们的治疗效果。

具体而言,拜登宣布了一系列举措,旨在帮助患者更好地了解临床试验的相关信息,这些信息可能对于患者而言过于专业、难以理解,现在拜登提出的措施将有助于患者理解并加入临床试验。此外,还要通过临床试验进一步延长患者的生存期。拜登希望更多的研究数据能够公开发表。具体操作上,美国国立癌症研究所(NCI)将对临床试验网站进行一部分重新设计,使得患者更加简洁地浏览页面,掌握NCI支持的相关临床试验的信息。

拜登对《时代杂志》表示,网页经过改造之后,任何一个想要浏览网页获取信息的患者都可以通过常规的关键词来搜索到临床试验的相关信息,而不用再被晦涩难懂的医学术语困扰。此外,这些临床数据还对APP开发者和患者团体开放,以创造更多的定制化资源。比方说当地医院可以利用这些数据开发针对当地的临床试验搜索工具,就像现在人们常用的搜索当地餐厅、杂货店和电影院的APP一样。美国NIH表示将致力于把所有的临床试验数据数据库设计得更加人性化,以帮助患者更好地参与临床试验。

白宫宣布,将更好地加强FDA、药企和临床试验执行者的相互合作,通过修改受试者条款、优化对照组等方式设计更加高效的临床试验方案。拜登还宣布,将进一步提高临床试验的透明度,并加大对报告不实信息的药企或者人员的惩罚力度。借下来还会要求研究者发表临床结果总结,无论测试药物最终是否能够获批。拜登表示这些举措将有助于提升临床试验的安全性、可接受性以及影响力。

拜登表示,临床试验对研发高效的新药至关重要,然而至今只有不到5%的患者参与到临床试验中,仅仅是因为患者或者医生不知道应当怎样参加、参加什么临床试验,未来这一情况将得到改善。拜登的抗癌“登月计划”在去年发布,旨在降低癌症患者的死亡率,这也是拜登任期内影响长远的计划之一。

原始出处:

VP Biden announces new trials push for his ‘Cancer Moonshot’


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=199370, encodeId=f6771993e0fe, content=看过了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Wed May 17 23:09:06 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188618, encodeId=05671886182f, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4PNicOvbHfgIficrsEKztlD5yv1UnCFhnFmFU9yv1RHLflMRibWrppbsiccfMB8tT9HCkAr3zL2zVml/0, createdBy=89da1604922, createdName=䖝二, createdTime=Wed Apr 19 00:04:40 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083522, encodeId=a870208352266, content=<a href='/topic/show?id=4809e15927c' target=_blank style='color:#2F92EE;'>#登月计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71592, encryptionId=4809e15927c, topicName=登月计划)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Sun Feb 05 05:07:00 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149307, encodeId=2d9a14930e02, content=将更好地加强FDA、药企和临床试验执行者的相互合作,通过修改受试者条款、优化对照组等方式设计更加高效的临床试验方案, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151226/IMG567EB873985DE3928.jpg, createdBy=ea941622301, createdName=inter158, createdTime=Mon Oct 17 23:50:18 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143115, encodeId=52a01431156a, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 11:01:39 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139889, encodeId=600113988953, content=自吞噬对癌症会有效果吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:03:12 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139888, encodeId=e1fe13988879, content=希望早日攻克癌症, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:02:48 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139887, encodeId=5e7013988efd, content=旨在降低癌症患者的死亡率。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:01:54 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424168, encodeId=a2db142416881, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Oct 01 10:07:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137888, encodeId=eaa713e88898, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Sep 30 08:13:00 CST 2016, time=2016-09-30, status=1, ipAttribution=)]
    2017-05-17 130****4638

    看过了谢谢分享。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=199370, encodeId=f6771993e0fe, content=看过了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Wed May 17 23:09:06 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188618, encodeId=05671886182f, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4PNicOvbHfgIficrsEKztlD5yv1UnCFhnFmFU9yv1RHLflMRibWrppbsiccfMB8tT9HCkAr3zL2zVml/0, createdBy=89da1604922, createdName=䖝二, createdTime=Wed Apr 19 00:04:40 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083522, encodeId=a870208352266, content=<a href='/topic/show?id=4809e15927c' target=_blank style='color:#2F92EE;'>#登月计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71592, encryptionId=4809e15927c, topicName=登月计划)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Sun Feb 05 05:07:00 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149307, encodeId=2d9a14930e02, content=将更好地加强FDA、药企和临床试验执行者的相互合作,通过修改受试者条款、优化对照组等方式设计更加高效的临床试验方案, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151226/IMG567EB873985DE3928.jpg, createdBy=ea941622301, createdName=inter158, createdTime=Mon Oct 17 23:50:18 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143115, encodeId=52a01431156a, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 11:01:39 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139889, encodeId=600113988953, content=自吞噬对癌症会有效果吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:03:12 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139888, encodeId=e1fe13988879, content=希望早日攻克癌症, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:02:48 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139887, encodeId=5e7013988efd, content=旨在降低癌症患者的死亡率。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:01:54 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424168, encodeId=a2db142416881, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Oct 01 10:07:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137888, encodeId=eaa713e88898, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Sep 30 08:13:00 CST 2016, time=2016-09-30, status=1, ipAttribution=)]
    2017-04-19 䖝二

    挺好的

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=199370, encodeId=f6771993e0fe, content=看过了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Wed May 17 23:09:06 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188618, encodeId=05671886182f, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4PNicOvbHfgIficrsEKztlD5yv1UnCFhnFmFU9yv1RHLflMRibWrppbsiccfMB8tT9HCkAr3zL2zVml/0, createdBy=89da1604922, createdName=䖝二, createdTime=Wed Apr 19 00:04:40 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083522, encodeId=a870208352266, content=<a href='/topic/show?id=4809e15927c' target=_blank style='color:#2F92EE;'>#登月计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71592, encryptionId=4809e15927c, topicName=登月计划)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Sun Feb 05 05:07:00 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149307, encodeId=2d9a14930e02, content=将更好地加强FDA、药企和临床试验执行者的相互合作,通过修改受试者条款、优化对照组等方式设计更加高效的临床试验方案, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151226/IMG567EB873985DE3928.jpg, createdBy=ea941622301, createdName=inter158, createdTime=Mon Oct 17 23:50:18 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143115, encodeId=52a01431156a, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 11:01:39 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139889, encodeId=600113988953, content=自吞噬对癌症会有效果吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:03:12 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139888, encodeId=e1fe13988879, content=希望早日攻克癌症, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:02:48 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139887, encodeId=5e7013988efd, content=旨在降低癌症患者的死亡率。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:01:54 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424168, encodeId=a2db142416881, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Oct 01 10:07:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137888, encodeId=eaa713e88898, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Sep 30 08:13:00 CST 2016, time=2016-09-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=199370, encodeId=f6771993e0fe, content=看过了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Wed May 17 23:09:06 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188618, encodeId=05671886182f, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4PNicOvbHfgIficrsEKztlD5yv1UnCFhnFmFU9yv1RHLflMRibWrppbsiccfMB8tT9HCkAr3zL2zVml/0, createdBy=89da1604922, createdName=䖝二, createdTime=Wed Apr 19 00:04:40 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083522, encodeId=a870208352266, content=<a href='/topic/show?id=4809e15927c' target=_blank style='color:#2F92EE;'>#登月计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71592, encryptionId=4809e15927c, topicName=登月计划)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Sun Feb 05 05:07:00 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149307, encodeId=2d9a14930e02, content=将更好地加强FDA、药企和临床试验执行者的相互合作,通过修改受试者条款、优化对照组等方式设计更加高效的临床试验方案, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151226/IMG567EB873985DE3928.jpg, createdBy=ea941622301, createdName=inter158, createdTime=Mon Oct 17 23:50:18 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143115, encodeId=52a01431156a, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 11:01:39 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139889, encodeId=600113988953, content=自吞噬对癌症会有效果吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:03:12 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139888, encodeId=e1fe13988879, content=希望早日攻克癌症, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:02:48 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139887, encodeId=5e7013988efd, content=旨在降低癌症患者的死亡率。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:01:54 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424168, encodeId=a2db142416881, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Oct 01 10:07:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137888, encodeId=eaa713e88898, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Sep 30 08:13:00 CST 2016, time=2016-09-30, status=1, ipAttribution=)]
    2016-10-17 inter158

    将更好地加强FDA、药企和临床试验执行者的相互合作,通过修改受试者条款、优化对照组等方式设计更加高效的临床试验方案

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=199370, encodeId=f6771993e0fe, content=看过了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Wed May 17 23:09:06 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188618, encodeId=05671886182f, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4PNicOvbHfgIficrsEKztlD5yv1UnCFhnFmFU9yv1RHLflMRibWrppbsiccfMB8tT9HCkAr3zL2zVml/0, createdBy=89da1604922, createdName=䖝二, createdTime=Wed Apr 19 00:04:40 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083522, encodeId=a870208352266, content=<a href='/topic/show?id=4809e15927c' target=_blank style='color:#2F92EE;'>#登月计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71592, encryptionId=4809e15927c, topicName=登月计划)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Sun Feb 05 05:07:00 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149307, encodeId=2d9a14930e02, content=将更好地加强FDA、药企和临床试验执行者的相互合作,通过修改受试者条款、优化对照组等方式设计更加高效的临床试验方案, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151226/IMG567EB873985DE3928.jpg, createdBy=ea941622301, createdName=inter158, createdTime=Mon Oct 17 23:50:18 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143115, encodeId=52a01431156a, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 11:01:39 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139889, encodeId=600113988953, content=自吞噬对癌症会有效果吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:03:12 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139888, encodeId=e1fe13988879, content=希望早日攻克癌症, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:02:48 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139887, encodeId=5e7013988efd, content=旨在降低癌症患者的死亡率。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:01:54 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424168, encodeId=a2db142416881, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Oct 01 10:07:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137888, encodeId=eaa713e88898, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Sep 30 08:13:00 CST 2016, time=2016-09-30, status=1, ipAttribution=)]
    2016-10-10 1e10c84am36(暂无匿称)

    文章很好,继续关注

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=199370, encodeId=f6771993e0fe, content=看过了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Wed May 17 23:09:06 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188618, encodeId=05671886182f, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4PNicOvbHfgIficrsEKztlD5yv1UnCFhnFmFU9yv1RHLflMRibWrppbsiccfMB8tT9HCkAr3zL2zVml/0, createdBy=89da1604922, createdName=䖝二, createdTime=Wed Apr 19 00:04:40 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083522, encodeId=a870208352266, content=<a href='/topic/show?id=4809e15927c' target=_blank style='color:#2F92EE;'>#登月计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71592, encryptionId=4809e15927c, topicName=登月计划)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Sun Feb 05 05:07:00 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149307, encodeId=2d9a14930e02, content=将更好地加强FDA、药企和临床试验执行者的相互合作,通过修改受试者条款、优化对照组等方式设计更加高效的临床试验方案, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151226/IMG567EB873985DE3928.jpg, createdBy=ea941622301, createdName=inter158, createdTime=Mon Oct 17 23:50:18 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143115, encodeId=52a01431156a, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 11:01:39 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139889, encodeId=600113988953, content=自吞噬对癌症会有效果吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:03:12 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139888, encodeId=e1fe13988879, content=希望早日攻克癌症, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:02:48 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139887, encodeId=5e7013988efd, content=旨在降低癌症患者的死亡率。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:01:54 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424168, encodeId=a2db142416881, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Oct 01 10:07:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137888, encodeId=eaa713e88898, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Sep 30 08:13:00 CST 2016, time=2016-09-30, status=1, ipAttribution=)]
    2016-10-04 Carlos007

    自吞噬对癌症会有效果吗

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=199370, encodeId=f6771993e0fe, content=看过了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Wed May 17 23:09:06 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188618, encodeId=05671886182f, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4PNicOvbHfgIficrsEKztlD5yv1UnCFhnFmFU9yv1RHLflMRibWrppbsiccfMB8tT9HCkAr3zL2zVml/0, createdBy=89da1604922, createdName=䖝二, createdTime=Wed Apr 19 00:04:40 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083522, encodeId=a870208352266, content=<a href='/topic/show?id=4809e15927c' target=_blank style='color:#2F92EE;'>#登月计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71592, encryptionId=4809e15927c, topicName=登月计划)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Sun Feb 05 05:07:00 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149307, encodeId=2d9a14930e02, content=将更好地加强FDA、药企和临床试验执行者的相互合作,通过修改受试者条款、优化对照组等方式设计更加高效的临床试验方案, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151226/IMG567EB873985DE3928.jpg, createdBy=ea941622301, createdName=inter158, createdTime=Mon Oct 17 23:50:18 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143115, encodeId=52a01431156a, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 11:01:39 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139889, encodeId=600113988953, content=自吞噬对癌症会有效果吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:03:12 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139888, encodeId=e1fe13988879, content=希望早日攻克癌症, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:02:48 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139887, encodeId=5e7013988efd, content=旨在降低癌症患者的死亡率。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:01:54 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424168, encodeId=a2db142416881, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Oct 01 10:07:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137888, encodeId=eaa713e88898, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Sep 30 08:13:00 CST 2016, time=2016-09-30, status=1, ipAttribution=)]
    2016-10-04 Carlos007

    希望早日攻克癌症

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=199370, encodeId=f6771993e0fe, content=看过了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Wed May 17 23:09:06 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188618, encodeId=05671886182f, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4PNicOvbHfgIficrsEKztlD5yv1UnCFhnFmFU9yv1RHLflMRibWrppbsiccfMB8tT9HCkAr3zL2zVml/0, createdBy=89da1604922, createdName=䖝二, createdTime=Wed Apr 19 00:04:40 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083522, encodeId=a870208352266, content=<a href='/topic/show?id=4809e15927c' target=_blank style='color:#2F92EE;'>#登月计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71592, encryptionId=4809e15927c, topicName=登月计划)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Sun Feb 05 05:07:00 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149307, encodeId=2d9a14930e02, content=将更好地加强FDA、药企和临床试验执行者的相互合作,通过修改受试者条款、优化对照组等方式设计更加高效的临床试验方案, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151226/IMG567EB873985DE3928.jpg, createdBy=ea941622301, createdName=inter158, createdTime=Mon Oct 17 23:50:18 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143115, encodeId=52a01431156a, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 11:01:39 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139889, encodeId=600113988953, content=自吞噬对癌症会有效果吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:03:12 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139888, encodeId=e1fe13988879, content=希望早日攻克癌症, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:02:48 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139887, encodeId=5e7013988efd, content=旨在降低癌症患者的死亡率。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:01:54 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424168, encodeId=a2db142416881, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Oct 01 10:07:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137888, encodeId=eaa713e88898, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Sep 30 08:13:00 CST 2016, time=2016-09-30, status=1, ipAttribution=)]
    2016-10-04 Carlos007

    旨在降低癌症患者的死亡率。

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=199370, encodeId=f6771993e0fe, content=看过了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Wed May 17 23:09:06 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188618, encodeId=05671886182f, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4PNicOvbHfgIficrsEKztlD5yv1UnCFhnFmFU9yv1RHLflMRibWrppbsiccfMB8tT9HCkAr3zL2zVml/0, createdBy=89da1604922, createdName=䖝二, createdTime=Wed Apr 19 00:04:40 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083522, encodeId=a870208352266, content=<a href='/topic/show?id=4809e15927c' target=_blank style='color:#2F92EE;'>#登月计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71592, encryptionId=4809e15927c, topicName=登月计划)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Sun Feb 05 05:07:00 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149307, encodeId=2d9a14930e02, content=将更好地加强FDA、药企和临床试验执行者的相互合作,通过修改受试者条款、优化对照组等方式设计更加高效的临床试验方案, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151226/IMG567EB873985DE3928.jpg, createdBy=ea941622301, createdName=inter158, createdTime=Mon Oct 17 23:50:18 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143115, encodeId=52a01431156a, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 11:01:39 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139889, encodeId=600113988953, content=自吞噬对癌症会有效果吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:03:12 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139888, encodeId=e1fe13988879, content=希望早日攻克癌症, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:02:48 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139887, encodeId=5e7013988efd, content=旨在降低癌症患者的死亡率。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:01:54 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424168, encodeId=a2db142416881, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Oct 01 10:07:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137888, encodeId=eaa713e88898, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Sep 30 08:13:00 CST 2016, time=2016-09-30, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=199370, encodeId=f6771993e0fe, content=看过了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Wed May 17 23:09:06 CST 2017, time=2017-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=188618, encodeId=05671886182f, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4PNicOvbHfgIficrsEKztlD5yv1UnCFhnFmFU9yv1RHLflMRibWrppbsiccfMB8tT9HCkAr3zL2zVml/0, createdBy=89da1604922, createdName=䖝二, createdTime=Wed Apr 19 00:04:40 CST 2017, time=2017-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083522, encodeId=a870208352266, content=<a href='/topic/show?id=4809e15927c' target=_blank style='color:#2F92EE;'>#登月计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71592, encryptionId=4809e15927c, topicName=登月计划)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Sun Feb 05 05:07:00 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149307, encodeId=2d9a14930e02, content=将更好地加强FDA、药企和临床试验执行者的相互合作,通过修改受试者条款、优化对照组等方式设计更加高效的临床试验方案, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151226/IMG567EB873985DE3928.jpg, createdBy=ea941622301, createdName=inter158, createdTime=Mon Oct 17 23:50:18 CST 2016, time=2016-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143115, encodeId=52a01431156a, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 11:01:39 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139889, encodeId=600113988953, content=自吞噬对癌症会有效果吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:03:12 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139888, encodeId=e1fe13988879, content=希望早日攻克癌症, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:02:48 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139887, encodeId=5e7013988efd, content=旨在降低癌症患者的死亡率。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160923/IMG57E54D670B3C08868.jpg, createdBy=e90b1956497, createdName=Carlos007, createdTime=Tue Oct 04 12:01:54 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424168, encodeId=a2db142416881, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sat Oct 01 10:07:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137888, encodeId=eaa713e88898, content=了解了解!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Sep 30 08:13:00 CST 2016, time=2016-09-30, status=1, ipAttribution=)]
    2016-09-30 1dd8c52fm63(暂无匿称)

    了解了解!

    0

相关资讯

紧追辉瑞!FDA授予诺华新型抗癌药LEE011治疗HR+/HER2-乳腺癌的突破性药物资格(BTD)

2016年8月5日讯,瑞士制药巨头诺华(Novartis)新型口服靶向抗癌药CDK4/6抑制剂LEE011(ribociclib)近日在美国监管方面传来喜讯。美国食品和药物管理局(FDA)已授予LEE011突破性药物资格(BTD),联合来该公司激素疗法Femara(品牌名:弗隆,通用名:letrozole,来曲唑)用于激素受体阳性/人类表皮生长因子受体2阴性(HR+/HER2-)晚期或转移性乳腺癌

专访北大肿瘤医院院长:中国抗癌之路怎么走

近日,一种被误读为“用小苏打‘饿死’癌细胞”的抗癌疗法引发热议。虽是讹传,但表明“抗癌”话题公众关注度颇高。多种因素作用下,全球癌症发病率不断攀升,抗癌成为医学界热点研究方向,中国也不例外。 今年年初美国政府提出的抗癌“登月计划”近日有了新的进展,由美国癌症专家组成的“蓝丝带顾问咨询委员会”建议,应在免疫疗法、数据共享和建立患者网络等十大领域重点投资,从而达到加快癌症研究的目的。

重磅!抗癌新药Keytruda进入中国!

好消息来了!硕果累累的抗癌新药Keytruda(中文名“派姆单抗”)通过了海南省出入境检验检疫局用药环境验收,入驻海南省肿瘤医院成美国际医学中心。这也意味着国内的癌症患者不用出境,就能用到国外最新的抗癌新药了!Keytruda由默沙东公司开发,是美国FDA批准的第一个PD-1免疫检测点抑制剂。作为新一类肿瘤疗法,Keytruda证实在包括肺癌、肾癌、黑色素瘤、头颈癌、膀胱癌、乳腺癌、肝癌、胃癌、食

Nat Chemistry:新发现或将快速筛选抗癌化合物

图片来源:www.phys.org 近日,刊登于国际杂志Nature Chemistry上的一项研究报告中,来自芝加哥大学的一组研究人员设计了一种方法来制造目前很多化学家都无法合成出的小型多节且连锁的化学结构,研究者认为,这些特殊的化学结构能够被用来筛选可以抵御癌症的新型化合物。 很多化学家都将分节或链环作为其开发的化学结构的一部分,但在分子尺度下合成出繁杂的新型物质是非常困难的,而这项研

全球抗癌研究“多路提速”直指突破

今年年初,美国总统奥巴马宣布发起抗癌“登月计划”,要求在现有基础上,两年内再为抗癌研究注入10亿美元的资金,目标是让癌症研究的相关进展速度翻一番,在5年内取得原本10年才能取得的成果。 本月早些时候,由癌症专家组成的美国“蓝丝带顾问咨询委员会”建议,抗癌“登月计划”应在免疫疗法、数据共享和建立患者网络等十大领域重点投资,加快癌症研究。 科学进步使抗癌研究具备了加速前进的基础,人

扒一扒“包治百病”的二甲双胍

导语:近些年,多项研究表明二甲双胍具有减重、延缓衰老、抗癌等作用。但是万物皆有两面性,即使是神药也不是十全十美的。二甲双胍自1957年问世以来,已经在国际上使用了近60年,在我国也已有近20年的使用经验。二甲双胍在各种2型糖尿病防治指南中,都处在一线用药的王牌地位。但二甲双胍的“野心”还不止于此——近年来,大量研究发现,二甲双胍还有抗衰老、抗癌等“特异功能”。今天我们就先来“肢解”二甲双胍的“

Baidu
map
Baidu
map
Baidu
map